Andrea Julie Bullock, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Pancreatic Ductal | 11 | 2024 | 1724 | 1.600 |
Why?
|
Pancreatic Neoplasms | 20 | 2024 | 5351 | 1.450 |
Why?
|
Liver Neoplasms | 9 | 2024 | 4319 | 0.840 |
Why?
|
Adenocarcinoma | 10 | 2024 | 6315 | 0.790 |
Why?
|
Tongue Neoplasms | 1 | 2022 | 183 | 0.710 |
Why?
|
Intestinal Pseudo-Obstruction | 1 | 2019 | 49 | 0.680 |
Why?
|
Lupus Erythematosus, Discoid | 1 | 2019 | 61 | 0.630 |
Why?
|
Carcinoma, Hepatocellular | 5 | 2024 | 2299 | 0.560 |
Why?
|
Colorectal Neoplasms | 4 | 2024 | 6853 | 0.550 |
Why?
|
Budd-Chiari Syndrome | 1 | 2016 | 24 | 0.540 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1728 | 0.530 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 11712 | 0.530 |
Why?
|
Leucovorin | 4 | 2022 | 641 | 0.510 |
Why?
|
Remission, Spontaneous | 1 | 2016 | 384 | 0.500 |
Why?
|
CA-19-9 Antigen | 4 | 2024 | 106 | 0.480 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2016 | 167 | 0.440 |
Why?
|
Health Care Costs | 2 | 2020 | 3258 | 0.440 |
Why?
|
Fluorouracil | 4 | 2022 | 1631 | 0.410 |
Why?
|
Deoxycytidine | 6 | 2020 | 873 | 0.400 |
Why?
|
Albumins | 5 | 2021 | 575 | 0.380 |
Why?
|
Mothers | 1 | 2020 | 2186 | 0.340 |
Why?
|
Esophageal Neoplasms | 1 | 2019 | 1648 | 0.330 |
Why?
|
Child Development | 1 | 2020 | 2285 | 0.320 |
Why?
|
Neoplasm Metastasis | 4 | 2024 | 4902 | 0.310 |
Why?
|
Caregivers | 1 | 2020 | 2224 | 0.310 |
Why?
|
Yttrium Radioisotopes | 3 | 2024 | 107 | 0.300 |
Why?
|
Cholangiocarcinoma | 2 | 2024 | 550 | 0.290 |
Why?
|
Bile Duct Neoplasms | 2 | 2024 | 602 | 0.290 |
Why?
|
Public Health | 1 | 2020 | 2653 | 0.290 |
Why?
|
Paclitaxel | 5 | 2021 | 1736 | 0.270 |
Why?
|
Venous Thrombosis | 1 | 2016 | 1299 | 0.270 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 4024 | 0.270 |
Why?
|
Microspheres | 3 | 2024 | 787 | 0.260 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2019 | 666 | 0.230 |
Why?
|
Drug Costs | 1 | 2012 | 1185 | 0.220 |
Why?
|
Comprehension | 2 | 2018 | 618 | 0.200 |
Why?
|
Cost of Illness | 1 | 2012 | 1940 | 0.200 |
Why?
|
Microsatellite Repeats | 1 | 2024 | 786 | 0.200 |
Why?
|
Mutation | 2 | 2024 | 29932 | 0.190 |
Why?
|
Hyaluronoglucosaminidase | 2 | 2020 | 135 | 0.190 |
Why?
|
Imitative Behavior | 1 | 2020 | 35 | 0.180 |
Why?
|
Microsatellite Instability | 1 | 2024 | 715 | 0.180 |
Why?
|
Neoplasm Regression, Spontaneous | 1 | 2019 | 46 | 0.170 |
Why?
|
Protein Kinase Inhibitors | 3 | 2024 | 5643 | 0.170 |
Why?
|
Middle Aged | 28 | 2024 | 220352 | 0.150 |
Why?
|
Decision Making | 1 | 2012 | 3925 | 0.150 |
Why?
|
Organometallic Compounds | 1 | 2021 | 662 | 0.150 |
Why?
|
Esophagogastric Junction | 1 | 2019 | 341 | 0.150 |
Why?
|
Aged | 24 | 2024 | 169152 | 0.150 |
Why?
|
Female | 31 | 2024 | 391270 | 0.140 |
Why?
|
Chemokine CCL2 | 1 | 2019 | 605 | 0.140 |
Why?
|
Aged, 80 and over | 11 | 2024 | 58995 | 0.140 |
Why?
|
Humans | 44 | 2024 | 760621 | 0.130 |
Why?
|
Germ-Line Mutation | 2 | 2022 | 1841 | 0.130 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2016 | 64 | 0.130 |
Why?
|
Gallbladder Neoplasms | 1 | 2017 | 190 | 0.130 |
Why?
|
alpha-Fetoproteins | 1 | 2016 | 222 | 0.130 |
Why?
|
BRCA1 Protein | 1 | 2022 | 1147 | 0.130 |
Why?
|
Male | 29 | 2024 | 359744 | 0.130 |
Why?
|
Cholecystectomy | 1 | 2017 | 406 | 0.120 |
Why?
|
Internet | 2 | 2018 | 3078 | 0.120 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 4312 | 0.120 |
Why?
|
Neuroendocrine Tumors | 1 | 2021 | 650 | 0.120 |
Why?
|
Ultrasonography | 2 | 2019 | 5961 | 0.120 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 2 | 2015 | 436 | 0.120 |
Why?
|
Proto-Oncogene Proteins | 2 | 2018 | 4490 | 0.120 |
Why?
|
Enoxaparin | 2 | 2017 | 397 | 0.120 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 2943 | 0.120 |
Why?
|
Kidney Cortex Necrosis | 1 | 2013 | 6 | 0.120 |
Why?
|
Cholecalciferol | 1 | 2019 | 550 | 0.110 |
Why?
|
Consumer Health Information | 1 | 2016 | 209 | 0.110 |
Why?
|
Nephrectomy | 1 | 2019 | 1016 | 0.110 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 734 | 0.110 |
Why?
|
STAT3 Transcription Factor | 1 | 2018 | 877 | 0.110 |
Why?
|
Neoplasms | 4 | 2020 | 22072 | 0.110 |
Why?
|
Life Expectancy | 1 | 2020 | 1248 | 0.110 |
Why?
|
Portal Vein | 1 | 2016 | 429 | 0.110 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13630 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9276 | 0.110 |
Why?
|
Vena Cava, Inferior | 1 | 2016 | 458 | 0.110 |
Why?
|
Sphingosine | 1 | 2015 | 308 | 0.100 |
Why?
|
Patient Education as Topic | 2 | 2020 | 2315 | 0.100 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3446 | 0.100 |
Why?
|
Lysophospholipids | 1 | 2015 | 339 | 0.100 |
Why?
|
Carcinoma, Renal Cell | 2 | 2019 | 3218 | 0.100 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13262 | 0.100 |
Why?
|
Fatal Outcome | 1 | 2016 | 1832 | 0.090 |
Why?
|
Lymph Node Excision | 1 | 2017 | 1303 | 0.090 |
Why?
|
Thromboplastin | 1 | 2012 | 286 | 0.090 |
Why?
|
Serine Endopeptidases | 1 | 2016 | 1021 | 0.090 |
Why?
|
Embolization, Therapeutic | 1 | 2020 | 1413 | 0.090 |
Why?
|
Vitamins | 1 | 2019 | 1634 | 0.090 |
Why?
|
Thromboembolism | 2 | 2017 | 1017 | 0.090 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2011 | 345 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2020 | 2781 | 0.080 |
Why?
|
Early Detection of Cancer | 2 | 2020 | 3202 | 0.080 |
Why?
|
Palliative Care | 2 | 2020 | 3607 | 0.080 |
Why?
|
Catheter Ablation | 1 | 2021 | 2758 | 0.070 |
Why?
|
Hepatitis C, Chronic | 1 | 2016 | 1031 | 0.070 |
Why?
|
Pilot Projects | 1 | 2020 | 8555 | 0.070 |
Why?
|
Pancreas | 2 | 2024 | 1677 | 0.070 |
Why?
|
Dietary Supplements | 1 | 2019 | 3392 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3610 | 0.070 |
Why?
|
Lymph Nodes | 1 | 2017 | 3486 | 0.070 |
Why?
|
Hyaluronic Acid | 2 | 2020 | 482 | 0.060 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2006 | 214 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5423 | 0.060 |
Why?
|
Adult | 12 | 2024 | 219994 | 0.060 |
Why?
|
Carbolines | 1 | 2006 | 288 | 0.060 |
Why?
|
Retrospective Studies | 7 | 2024 | 80372 | 0.060 |
Why?
|
Prognosis | 6 | 2020 | 29658 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2019 | 6828 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39261 | 0.050 |
Why?
|
Pancreatectomy | 2 | 2018 | 810 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2013 | 2919 | 0.050 |
Why?
|
Erectile Dysfunction | 1 | 2006 | 452 | 0.050 |
Why?
|
Antibodies, Monoclonal | 2 | 2019 | 9185 | 0.050 |
Why?
|
Radiosurgery | 1 | 2011 | 1343 | 0.050 |
Why?
|
Cytidine | 1 | 2021 | 65 | 0.050 |
Why?
|
Metabolic Clearance Rate | 1 | 2021 | 361 | 0.050 |
Why?
|
Gallium Radioisotopes | 1 | 2021 | 195 | 0.050 |
Why?
|
Treatment Outcome | 7 | 2024 | 65017 | 0.050 |
Why?
|
Cohort Studies | 2 | 2020 | 41335 | 0.040 |
Why?
|
Half-Life | 1 | 2021 | 652 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 10790 | 0.040 |
Why?
|
Liver | 1 | 2016 | 7509 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2020 | 26181 | 0.040 |
Why?
|
Multimedia | 1 | 2020 | 74 | 0.040 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2021 | 296 | 0.040 |
Why?
|
Medical Oncology | 1 | 2012 | 2313 | 0.040 |
Why?
|
Spasm | 1 | 2020 | 131 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 36290 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2019 | 3529 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2015 | 5253 | 0.040 |
Why?
|
Insurance, Health | 1 | 2012 | 2501 | 0.040 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2002 | 370 | 0.040 |
Why?
|
Niacinamide | 1 | 2021 | 414 | 0.040 |
Why?
|
Receptor, Notch2 | 1 | 2019 | 87 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2016 | 7850 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4899 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 877 | 0.040 |
Why?
|
Acetaminophen | 1 | 2002 | 553 | 0.040 |
Why?
|
Physician-Patient Relations | 1 | 2012 | 3242 | 0.040 |
Why?
|
Medicaid | 1 | 2012 | 2815 | 0.040 |
Why?
|
Infant | 1 | 2020 | 36060 | 0.040 |
Why?
|
Chemokine CXCL10 | 1 | 2019 | 316 | 0.040 |
Why?
|
Phenylurea Compounds | 1 | 2021 | 529 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2021 | 10827 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6544 | 0.040 |
Why?
|
Pancreatitis, Chronic | 1 | 2020 | 281 | 0.040 |
Why?
|
Hyponatremia | 1 | 2020 | 279 | 0.040 |
Why?
|
Child, Preschool | 1 | 2020 | 42063 | 0.040 |
Why?
|
Radionuclide Imaging | 1 | 2021 | 1975 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2019 | 340 | 0.040 |
Why?
|
Lung | 1 | 2016 | 9994 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11152 | 0.040 |
Why?
|
Area Under Curve | 1 | 2021 | 1636 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2012 | 3986 | 0.040 |
Why?
|
Anticoagulants | 1 | 2012 | 4897 | 0.030 |
Why?
|
Organoplatinum Compounds | 1 | 2018 | 410 | 0.030 |
Why?
|
Pancreatic Cyst | 1 | 2020 | 367 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 17790 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2018 | 8515 | 0.030 |
Why?
|
Organizations, Nonprofit | 1 | 2016 | 105 | 0.030 |
Why?
|
Organoids | 1 | 2022 | 729 | 0.030 |
Why?
|
Disease Progression | 3 | 2020 | 13502 | 0.030 |
Why?
|
Death | 1 | 2020 | 678 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2018 | 3616 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 544 | 0.030 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2017 | 231 | 0.030 |
Why?
|
Government | 1 | 2016 | 160 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2020 | 12427 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 861 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2018 | 558 | 0.030 |
Why?
|
Survival Rate | 2 | 2020 | 12808 | 0.030 |
Why?
|
Metabolomics | 1 | 2023 | 1628 | 0.030 |
Why?
|
Pancreaticoduodenectomy | 1 | 2017 | 508 | 0.030 |
Why?
|
Ownership | 1 | 2016 | 339 | 0.030 |
Why?
|
Medicare | 1 | 2012 | 6786 | 0.030 |
Why?
|
Mass Media | 1 | 2016 | 300 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12531 | 0.030 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2018 | 607 | 0.030 |
Why?
|
Renal Veins | 1 | 2013 | 102 | 0.030 |
Why?
|
Genes, Lethal | 1 | 2013 | 225 | 0.030 |
Why?
|
United States | 4 | 2020 | 72461 | 0.030 |
Why?
|
Cell Respiration | 1 | 2013 | 202 | 0.030 |
Why?
|
Fatigue | 1 | 2020 | 1544 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2021 | 1958 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10182 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 2282 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20509 | 0.030 |
Why?
|
Incidental Findings | 1 | 2017 | 698 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2017 | 1007 | 0.030 |
Why?
|
Complementary Therapies | 1 | 2016 | 486 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2017 | 1791 | 0.030 |
Why?
|
Heart Failure | 1 | 2016 | 11847 | 0.020 |
Why?
|
Cell-Derived Microparticles | 1 | 2012 | 161 | 0.020 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2012 | 418 | 0.020 |
Why?
|
Aspirin | 1 | 2002 | 3364 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2018 | 9411 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2018 | 10446 | 0.020 |
Why?
|
Carcinoma in Situ | 1 | 2016 | 796 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2821 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5201 | 0.020 |
Why?
|
Propensity Score | 1 | 2017 | 1928 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 2014 | 0.020 |
Why?
|
DNA Methylation | 1 | 2024 | 4373 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4107 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2203 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2013 | 1617 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1895 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2514 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2019 | 3484 | 0.020 |
Why?
|
Information Dissemination | 1 | 2016 | 1131 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2803 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2698 | 0.020 |
Why?
|
Fibrinolytic Agents | 1 | 2017 | 2167 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2013 | 1674 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2015 | 16939 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 54303 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3584 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3844 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2013 | 21025 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2015 | 1741 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2754 | 0.020 |
Why?
|
Up-Regulation | 1 | 2015 | 4122 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 2138 | 0.020 |
Why?
|
Coitus | 1 | 2006 | 131 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12159 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14660 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 12965 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2021 | 6465 | 0.020 |
Why?
|
Young Adult | 1 | 2012 | 58741 | 0.020 |
Why?
|
Vitamin D | 1 | 2019 | 3291 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 3075 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2640 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2011 | 2897 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2018 | 11071 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6965 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10344 | 0.010 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 1660 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18416 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 8056 | 0.010 |
Why?
|
Thrombosis | 1 | 2013 | 3052 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2011 | 8552 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 24123 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2016 | 22053 | 0.010 |
Why?
|
Mice | 2 | 2015 | 81208 | 0.010 |
Why?
|
Drug Utilization | 1 | 2002 | 1195 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 40165 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18137 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2006 | 3448 | 0.010 |
Why?
|
Animals | 2 | 2015 | 167963 | 0.010 |
Why?
|
Signal Transduction | 1 | 2013 | 23376 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2002 | 25942 | 0.000 |
Why?
|